抗PD-L2免疫疗法通过IL-17和IFNγ信号传递对老年宿主中的黑色素瘤有效
Carlos O Ontiveros1,2,3, Myrna G Garcia1,2,3, Clare E Murray1,2,3
1South Texas Medical Scientist Training Program, University of Texas Health, San Antonio, TX, USA.
Nature communications
|November 19, 2025
概括
抗PD-L2疗法在患有黑色素瘤的老年小鼠中显示出有效性,与年轻小鼠不同. 这种依赖年龄的反应与介质蛋白-17 (IL-17) 有关,为癌症免疫治疗提供了新的途径.
科学领域:
- 免疫学 免疫学 免疫学
- 癌症生物学 癌症生物学
- 衰老研究研究 衰老研究
背景情况:
- 编程细胞死亡蛋白1 (PD-1) 和它的配体 (PD-L1,PD-L2) 是免疫检查关键点.
- 针对PD-L1 (αPD-L1) 的抗体是已知的癌症免疫疗法.
- 针对PD-L2 (αPD-L2) 的抗体的治疗潜力仍未得到充分研究,特别是在与年龄相关的疗效方面.
研究的目的:
- 为了研究αPD-L2疗法的疗效,在年轻的与老年小鼠携带B16黑色素瘤.
- 阐明基于年龄的αPD-L2疗效背后的机制,重点关注IL-17.
- 探索增强αPD-L2免疫疗法的潜在策略.
主要方法:
- 在年轻和老年B16黑色素瘤携带小鼠的αPD-L2疗效的比较.
- 评估瘤透免疫细胞 (IFN-γ+) 和细胞因子的产生.
- 使用缺少IL-17的小鼠和外源IL-17的管理来评估IL-17的作用.
- 在不同的瘤模型和年龄组中测试αPD-L2的疗效.
主要成果:
- αPD-L2在老年小鼠中有效,但在患有B16黑色素瘤的年轻小鼠中无效.
- 在老年小鼠中的疗效与瘤透的干扰素-γ+细胞和IFN-γ生产的增加相关,依赖于IL-17.
- 在另一种瘤类型中,αPD-L2疗效随着年龄的增长而改善.
- 外源IL-17在年轻小鼠中恢复了αPD-L2的有效性,突出了IL-17在老年免疫反应中的关键作用.
结论:
- αPD-L2免疫疗法具有年龄相关的疗效,在老年宿主中更有效.
- 在老年黑色素瘤携带小鼠中,IL-17信号传递是αPD-L2疗效的关键调解者.
- 了解αPD-L2反应的年龄相关机制,可以为改进癌症免疫治疗的策略提供信息,包括对年轻患者和耐药瘤的免疫治疗.
更多相关视频
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
1.7K
10:13Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
Published on: May 6, 2019
9.5K
相关概念视频
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
01:24T Cell Types and Functions
2.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.1K